This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Food and Drug Administration (FDA) approved Januvia in 2006. No generic version of Januvia is available in the United States, but this could change in 2026 when the main patent expires. The first patent, covering the dihydrogen phosphate salt of sitagliptin, expires on November 24, 2026.
The memorandum outlines CMS’s priorities and timeline for the Initial Price Applicability Year 2026. The topics focus on issues relevant in the first three years of the Negotiation Program—2026 to 2028. Method for applying the MFP across different dosage forms and strengths of a selected drug.
Koblitz — For years, submitting a Suitability Petition has been like screaming into a void: You’d be lucky if FDA ever responds. This has been a big problem because FDA’s inattentiveness can delay entry of certain types of ANDAs for years—often resulting in the ANDA applicant’s abandonment of the Suitability Petition. Under 21 C.F.R.
Clinical studies on Ozempic’s effectiveness for insulin resistance Ozempic has not been officially approved by the Food and Drug Administration (FDA) to treat insulin resistance. These findings have spurred further research, with ongoing clinical trials set to conclude in October 2026. mg once a week.
AstraZeneca also claimed that CMS’s revised guidance on the Negotiation Program for Price Applicability Year 2026 (“Guidance”) interpreted the IRA in two very faulty ways, which violated the Administrative Procedure Act (APA) and harmed and will continue to harm the company. The court found numerous flaws with this argument.
This recent decision by the EC follows approval of Tyruko ® (natalizumab) by the US Food and Drug Administration (FDA) last month for the same indication. Tyruko ® has the same strength/dosage form, intravenous (IV) route of administration, dosing regimen and presentation as the reference medicine, according to Sandoz.
Generic perampanel won’t be available until 2026 at the earliest, but even that is uncertain. . The dosage strength does not affect the retail price, but a prescription for Fycompa oral suspension costs more than tablets. However, Fycompa patients do have other options to save. . What is the generic for Fycompa?
It is approved by the Food and Drug Administration (FDA) to help manage blood sugar levels in individuals with diabetes mellitus. The earliest the patent for the brand name may expire is 2026 , after which a generic version may be made available. Fiasp Flextouch is a rapid- or fast-acting insulin pen containing insulin aspart.
Active Ingredient: dulaglutide Dosage Forms & Strengths: Injection: 0.75 Some of its FDA-approved competitors include: Patents7 Eli Lilly carries big expectations from Trulicity to boost its revenue. In the US, Trulicity is protected by a compound patent (2027) and by biologics data protection (2026). mL, 3 mg/0.5
threshold by 2026. In Aug’21, the US FDA cleared QSam’s IND application for CycloSam. In Jun’21, the company initiated the evaluation of FAP-2286 in a P-I/II clinical trial (LuMIERE) following the US FDA’s IND clearance. In Sep’21, the US FDA granted DUNP19 an ODD for Osteosarcoma.
Livornese & JP Ellison — On November 8, 2024, FDA issued a proposed order to remove the oral decongestant ingredient phenylephrine (including both phenylephrine hydrochloride and phenylephrine bitartrate) (collectively, PE) from the OTC monograph on the basis of a lack of effectiveness. By Deborah L.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content